RU2014120465A - Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул - Google Patents

Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул Download PDF

Info

Publication number
RU2014120465A
RU2014120465A RU2014120465/15A RU2014120465A RU2014120465A RU 2014120465 A RU2014120465 A RU 2014120465A RU 2014120465/15 A RU2014120465/15 A RU 2014120465/15A RU 2014120465 A RU2014120465 A RU 2014120465A RU 2014120465 A RU2014120465 A RU 2014120465A
Authority
RU
Russia
Prior art keywords
cell
changing
nanoparticle
functionalized biocompatible
peptide
Prior art date
Application number
RU2014120465/15A
Other languages
English (en)
Inventor
Андраник Эндрю АПРИКЯН
Килиан ДИЛЛ
Original Assignee
Стемдженикс, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стемдженикс, Инк filed Critical Стемдженикс, Инк
Publication of RU2014120465A publication Critical patent/RU2014120465A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/34—Belt retractors, e.g. reels
    • B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
    • B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/289—Energy-absorption curves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mechanical Engineering (AREA)
  • Toxicology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

1. Функционализированная биосовместимая наночастица, способная проникать сквозь мембрану клетки млекопитающего и доставлять множество биоактивных молекул для модулирования клеточной функции, включающая:центральную наночастицу с размером в интервале от 5 до 50 нм, которая имеет полимерное покрытие,множество функциональных групп, ковалентно присоединенных к полимерному покрытию, где множество биоактивных молекул присоединено к множеству функциональных групп, и где множество биоактивных молекул включает, по меньшей мере, пептид или белок, и где пептид способен проникать сквозь мембрану клетки млекопитающего и проникать в клетку, и где белок способен обеспечивать новую функциональность внутри клетки2. Функционализированная биосовместимая наночастица по п. 1, где наночастица включает железо.3. Функционализированная биосовместимая наночастица по п. 2, где пептид присоединен к белку.4. Функционализированная биосовместимая наночастица по п. 3, где пептид и белок каждый соединен с наночастицей посредством одной или нескольких вставленных линкерных молекул.5. Функционализированная биосовместимая наночастица по п. 1, где пептид включает от пяти до девяти основных аминокислот.6. Функционализированная биосовместимая наночастица по п. 1, где пептид включает девять или более основных аминокислот.7. Функционализированная биосовместимая наночастица по п. 5, где белок представляет собой транскрипционный фактор.8. Функционализированная биосовместимая наночастица по п. 7, где транскрипционный фактор выбран из группы, состоящей из Oct4, Sox2, Nanog, Lin28, сМус и Klf4.9. Способ изменения клеточной функциональности внутри клетки млекоп

Claims (14)

1. Функционализированная биосовместимая наночастица, способная проникать сквозь мембрану клетки млекопитающего и доставлять множество биоактивных молекул для модулирования клеточной функции, включающая:
центральную наночастицу с размером в интервале от 5 до 50 нм, которая имеет полимерное покрытие,
множество функциональных групп, ковалентно присоединенных к полимерному покрытию, где множество биоактивных молекул присоединено к множеству функциональных групп, и где множество биоактивных молекул включает, по меньшей мере, пептид или белок, и где пептид способен проникать сквозь мембрану клетки млекопитающего и проникать в клетку, и где белок способен обеспечивать новую функциональность внутри клетки
2. Функционализированная биосовместимая наночастица по п. 1, где наночастица включает железо.
3. Функционализированная биосовместимая наночастица по п. 2, где пептид присоединен к белку.
4. Функционализированная биосовместимая наночастица по п. 3, где пептид и белок каждый соединен с наночастицей посредством одной или нескольких вставленных линкерных молекул.
5. Функционализированная биосовместимая наночастица по п. 1, где пептид включает от пяти до девяти основных аминокислот.
6. Функционализированная биосовместимая наночастица по п. 1, где пептид включает девять или более основных аминокислот.
7. Функционализированная биосовместимая наночастица по п. 5, где белок представляет собой транскрипционный фактор.
8. Функционализированная биосовместимая наночастица по п. 7, где транскрипционный фактор выбран из группы, состоящей из Oct4, Sox2, Nanog, Lin28, сМус и Klf4.
9. Способ изменения клеточной функциональности внутри клетки млекопитающего, включающий введение эффективного количества функционализированной биосовместимой наночастицы по п. 1 в клетку и изменение клеточной функциональности внутри клетки.
10. Способ изменения клеточной функциональности внутри клетки млекопитающего по п. 9, где изменение клеточной функциональности включает изменение физико-химического свойства клетки.
11. Способ изменения клеточной функциональности внутри клетки млекопитающего по п. 9, где изменение клеточной функциональности включает изменение пролиферативного свойства клетки.
12. Способ изменения клеточной функциональности внутри клетки млекопитающего по п. 9, где изменение клеточной функциональности включает изменение способности выживаемости клетки.
13. Способ изменения клеточной функциональности внутри клетки млекопитающего по п. 9, где изменение клеточной функциональности включает изменение морфологического фенотипического свойства клетки.
14. Способ изменения клеточной функциональности внутри клетки млекопитающего по п.9, где изменение клеточной функциональности включает приобретенную способность клетки создавать новый клеточный тип, включающий стволовую клетку или более специализированный клеточный тип.
RU2014120465/15A 2011-10-21 2012-10-22 Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул RU2014120465A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550213P 2011-10-21 2011-10-21
US61/550,213 2011-10-21
PCT/US2012/061391 WO2013059831A1 (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018135567A Division RU2018135567A (ru) 2011-10-21 2012-10-22 Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул

Publications (1)

Publication Number Publication Date
RU2014120465A true RU2014120465A (ru) 2015-11-27

Family

ID=48141479

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018135567A RU2018135567A (ru) 2011-10-21 2012-10-22 Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул
RU2014120465/15A RU2014120465A (ru) 2011-10-21 2012-10-22 Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018135567A RU2018135567A (ru) 2011-10-21 2012-10-22 Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул

Country Status (14)

Country Link
US (1) US9675708B2 (ru)
EP (2) EP2769217A4 (ru)
JP (3) JP2014532628A (ru)
KR (3) KR20200040924A (ru)
CN (2) CN104094119A (ru)
AU (3) AU2012325723A1 (ru)
BR (1) BR112014009753B1 (ru)
CA (2) CA2853128C (ru)
HK (1) HK1201089A1 (ru)
IN (1) IN2014DN03224A (ru)
MX (3) MX367656B (ru)
RU (2) RU2018135567A (ru)
SG (2) SG11201401658SA (ru)
WO (1) WO2013059831A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
US10100332B2 (en) 2013-08-23 2018-10-16 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
US20170015975A1 (en) * 2014-02-10 2017-01-19 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
CN105440112A (zh) * 2015-12-07 2016-03-30 国家纳米科学中心 多肽-白蛋白偶联药物、其制备方法及应用
EP3463316A4 (en) * 2016-06-03 2020-05-27 Stemgenics, Inc. FUNCTIONALIZED NANOPARTICLES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS OF MAKING AND USING THE SAME
CN114634908A (zh) * 2016-06-03 2022-06-17 斯特姆詹尼克斯公司 用功能化纳米颗粒将人类体细胞直接重编程为选定的(预定的)分化细胞
EP3525831A4 (en) * 2016-10-11 2020-06-03 Stemgenics, Inc. NANOPARTICLES FUNCTIONALIZED WITH GENE EDITING TOOLS AND RELATED METHODS
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US11065345B2 (en) * 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US11701433B2 (en) 2017-06-05 2023-07-18 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN108287235B (zh) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
US20200326325A1 (en) 2019-04-12 2020-10-15 Lisa Diamond Nanosensor chip with compound nanopores
CN112111042B (zh) * 2019-06-21 2024-04-05 康码（上海）生物科技有限公司 一种生物磁性微球及其制备方法和使用方法
CN110642876A (zh) * 2019-10-10 2020-01-03 南京市口腔医院 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品
CN112472685B (zh) * 2020-12-10 2023-03-24 哈尔滨工业大学 一种杂化中性粒细胞机器人的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767635B1 (en) * 1999-09-14 2004-07-27 Biomedical Apherese Systeme Gmbh Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
CN101389314A (zh) 2005-03-14 2009-03-18 得克萨斯大学体系董事会 生物活性fus1肽和纳米颗粒-多肽复合物
KR101364374B1 (ko) * 2005-03-14 2014-02-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체
MX2007016039A (es) * 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
EP2099496A2 (en) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
US20080166412A1 (en) 2007-01-02 2008-07-10 Kiminobu Sugaya Methods and materials for stimulating proliferation of stem cell
KR100925689B1 (ko) * 2007-07-25 2009-11-10 한국생명공학연구원 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질
US8283344B2 (en) 2007-09-10 2012-10-09 Merck & Co., Inc. Method of treating inherited severe neutropenia
KR100951719B1 (ko) * 2007-10-02 2010-04-07 재단법인서울대학교산학협력재단 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도
AU2008329562A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
US11260133B2 (en) * 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
JP2012513218A (ja) * 2008-12-23 2012-06-14 ヴィヴォスクリプト，インコーポレイテッド 遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
AR076225A1 (es) * 2009-04-07 2011-05-26 Dow Agrosciences Llc Administracion de nanoparticulas revestidas de una secuencia de nucleasa especifica
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子

Also Published As

Publication number Publication date
CN106822868A (zh) 2017-06-13
EP3400956A1 (en) 2018-11-14
HK1201089A1 (en) 2015-08-21
WO2013059831A1 (en) 2013-04-25
SG11201401658SA (en) 2014-07-30
JP6560302B2 (ja) 2019-08-14
AU2020223737A1 (en) 2020-09-17
EP2769217A4 (en) 2015-06-03
CA2853128C (en) 2016-09-27
BR112014009753B1 (pt) 2020-09-15
JP2014532628A (ja) 2014-12-08
US20140342004A1 (en) 2014-11-20
CA2938661A1 (en) 2013-04-25
JP2017165781A (ja) 2017-09-21
EP2769217A1 (en) 2014-08-27
AU2018203848A1 (en) 2018-06-21
KR20190077124A (ko) 2019-07-02
MX367656B (es) 2019-08-29
MX2014004778A (es) 2014-10-17
SG10201601746TA (en) 2016-04-28
JP2018184485A (ja) 2018-11-22
BR112014009753A2 (pt) 2017-04-25
MX2018010696A (es) 2020-09-02
US9675708B2 (en) 2017-06-13
KR20200040924A (ko) 2020-04-20
AU2012325723A1 (en) 2014-05-15
CN104094119A (zh) 2014-10-08
KR20150001711A (ko) 2015-01-06
CA2853128A1 (en) 2013-04-25
RU2018135567A (ru) 2018-11-15
IN2014DN03224A (ru) 2015-05-22

Similar Documents

Publication Publication Date Title
RU2014120465A (ru) Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул
JP2014532628A5 (ru)
Wang et al. Recent advances in the fabrication, functionalization, and bioapplications of peptide hydrogels
Zhang et al. Protein-mimetic peptide nanofibers: Motif design, self-assembly synthesis, and sequence-specific biomedical applications
Shin et al. Three-dimensional electroconductive hyaluronic acid hydrogels incorporated with carbon nanotubes and polypyrrole by catechol-mediated dispersion enhance neurogenesis of human neural stem cells
Mohammadi Amirabad et al. Enhanced cardiac differentiation of human cardiovascular disease patient-specific induced pluripotent stem cells by applying unidirectional electrical pulses using aligned electroactive nanofibrous scaffolds
Wang et al. Ultrashort peptides and hyaluronic acid-based injectable composite hydrogels for sustained drug release and chronic diabetic wound healing
Chow et al. Peptide-based biopolymers in biomedicine and biotechnology
Guo et al. Parallel control over surface charge and wettability using polyelectrolyte architecture: effect on protein adsorption and cell adhesion
Borges et al. Nanoengineering hybrid supramolecular multilayered biomaterials using polysaccharides and self‐assembling peptide amphiphiles
Pramanik Short peptide-based smart thixotropic hydrogels
Shin et al. Stimulating effect of graphene oxide on myogenesis of C2C12 myoblasts on RGD peptide-decorated PLGA nanofiber matrices
Hortensius et al. The use of bioinspired alterations in the glycosaminoglycan content of collagen–GAG scaffolds to regulate cell activity
Chu et al. Long-term stability, high strength, and 3D printable alginate hydrogel for cartilage tissue engineering application
Patel et al. Hierarchically aligned fibrous hydrogel films through microfluidic self‐assembly of graphene and polysaccharides
DK2928512T3 (en) SCALABLE MANUFACTURE OF THREE-DIMENSIONAL ELASTIC CONSTRUCTIONS
Deming Preparation and development of block copolypeptide vesicles and hydrogels for biological and medical applications
WO2015080670A9 (en) Novel ultrashort hydrophobic peptides that self-assemble into nanofibrous hydrogels and their uses
Tsai et al. Electrospun chitosan–gelatin–polyvinyl alcohol hybrid nanofibrous mats: Production and characterization
Qin et al. Hierarchical self-assembly of a β-amyloid peptide derivative
Shin et al. Bio‐inspired immobilization of cell‐adhesive ligands on electrospun Nanofibrous patches for cell delivery
Hou et al. Self-Assembly and Hydrogelation of Coil–Sheet Poly (l-lysine)-block-poly (l-threonine) Block Copolypeptides
WO2017141204A3 (en) Biguanide grafted / modified biopolymers as drug delivery vehicles
Chibh et al. Recent advances in the fabrication and bio-medical applications of self-assembled dipeptide nanostructures
Tan et al. Peptide-based nanomaterials: self-assembly and applications